MARKET

CERC

CERC

Cerecor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.940
+0.040
+1.38%
After Hours: 2.980 +0.04 +1.36% 19:52 01/20 EST
OPEN
2.920
PREV CLOSE
2.900
HIGH
2.950
LOW
2.810
VOLUME
1.15M
TURNOVER
--
52 WEEK HIGH
5.02
52 WEEK LOW
1.520
MARKET CAP
256.44M
P/E (TTM)
-3.1981
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Cerecor announces proceeds from option to purchase additional shares, resulting in total gross proceeds of~$40.7M
Cerecor ([[CERC]] -1.0%) announces exercise by the underwriters of their option to purchase an additional 1,648,812 shares at a price to the public of $2.60/share.This increases the total offered through
Seekingalpha · 13h ago
Cerecor Raises Total Gross Proceeds of $40.7 Million After Underwriters Exercise Option to Buy Additional Shares
MT Newswires · 17h ago
Cerecor Announces Proceeds From Option To Purchase Additional Shares Of Common Stock, Bringing Public Offering Proceeds To $40.7M
ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (("Cerecor", NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of
Benzinga · 20h ago
Press Release: Cerecor Announces Proceeds from Option to Purchase Additional Shares of Common Stock Bringing Public Offering Proceeds to $40.7 Million
Dow Jones · 20h ago
Armistice Capital adds 2.5M Cerecor shares for $6.5M
Armistice Capital, holder of 10% shares of Cerecor (CERC) adds 2.5M common shares to its existing holding for the total transaction value of $6.5M.Post share acquisition, Capital direct holding is
Seekingalpha · 01/13 11:48
Cerecor Inc. Announces Closing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants
ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announc...
GlobeNewswire · 01/12 21:01
Sarepta Therapeutics, Velodyne Lidar leads the premarket losers' pack
Sarepta Therapeutics SRPT -48% as DMD gene therapy treatment fails to meet primary endpoint.Neoleukin Therapeutics NLTX -19% after receiving clinical hold letter from FDA related to CMC assay development for NL-201.Solid Biosciences SLDB -18% after Sarepta
Seekingalpha · 01/08 13:26
The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 7)
Benzinga · 01/08 12:25
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CERC. Analyze the recent business situations of Cerecor through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CERC stock price target is 8.00 with a high estimate of 9.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 84
Institutional Holdings: 49.93M
% Owned: 57.24%
Shares Outstanding: 87.22M
TypeInstitutionsShares
Increased
25
2.56M
New
13
-893.72K
Decreased
19
784.49K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
+0.05%
Key Executives
Chairman/Director
Sol Barer
Chief Executive Officer
Mike Cola
Chief Executive Officer/Director
Michael Cola
Chief Financial Officer/Chief Accounting Officer
Christopher Sullivan
Other
Jamie Harrell
Other
Garry Neil
Other
Jeff Wilkins
Director
Suzanne Bruhn
Director
Joseph Miller
Independent Director
Steven Boyd
Independent Director
Phil Gutry
Independent Director
Gilla Kaplan
Independent Director
Magnus Persson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CERC
Cerecor, Inc. is a biopharmaceutical company. The Company is focused on development and commercialization of treatments for pediatric and orphan diseases. Its pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The Company is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody which is developed for autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma. CERC-006 is an mTORC1/2 inhibitor which is developed as a treatment for Lymphatic Malformations (LM). CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes), monoclonal antibody is developed as a treatment for Pediatric Crohn's Disease.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cerecor Inc stock information, including NASDAQ:CERC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CERC stock methods without spending real money on the virtual paper trading platform.